Alternative names
MeOPP
IUPAC Name
1-(4-methoxyphenyl)piperazine
Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Discussion
1-(4-Methoxyphenyl)piperazine (MeOPP) is a piperazine derivative that appears to have mild stimulant effects (including euphoria) and some hallucinogenic properties. Very little information is available on this substance. MeOPP has never been licensed as a medicine. The first report of seized material containing MeOPP appeared in 2006 in the United Kingdom. Many suppliers market the substance as "legal ecstasy" or as a "legal high". Such products typically contain other piperazine derivatives in variable quantities. There are no published reports of non-fatal or fatal hospital admissions. No specific studies have been performed to determine the abuse or dependence potential.
Recommendation
Given the limited information available, and the current lack of evidence of abuse, the Expert Committee recommended that a critical review for 1-(4-methoxyphenyl)piperazine not be conducted at this time.
1-(4-Methoxyphenyl)piperazine (MeOPP) is a piperazine derivative that appears to have mild stimulant effects (including euphoria) and some hallucinogenic properties. Very little information is available on this substance. MeOPP has never been licensed as a medicine. The first report of seized material containing MeOPP appeared in 2006 in the United Kingdom. Many suppliers market the substance as "legal ecstasy" or as a "legal high". Such products typically contain other piperazine derivatives in variable quantities. There are no published reports of non-fatal or fatal hospital admissions. No specific studies have been performed to determine the abuse or dependence potential.
Recommendation
Given the limited information available, and the current lack of evidence of abuse, the Expert Committee recommended that a critical review for 1-(4-methoxyphenyl)piperazine not be conducted at this time.
ECDD Recommendation
No change in scheduling
Link to full TRS
who_trs_973_eng.pdf1.73 MB
MS Questionnaire Report